Undiagnosed Sleep Disorder Market Offers Growth Opportunities
| Publication Date | April 2008 |
|---|---|
| Publisher | Koncept Analytics |
| Product Type | Report |
| Pages | 31 |
| ISBN Number | not applicable |
| Product Code | KOA04269 |
Summary
There are more than 70 different sleep disorders but the most common ones include insomnia, sleep apnea, restless legs syndrome, and narcolepsy. One of the fastest growing sector in the sleep disorder treatment market is obstructive sleep apnea (OSA) products. OSA affects up to 18 million patients in the US with as many as 85% are undiagnosed. Similarly, 30 million are chronic sufferers of insomnia but only a third of chronic sufferers are receiving treatment. A key reason for this low percentage of people receiving treatment is the side effects associated with most of the insomnia drugs. Over 1.6 million Americans use some form of alternative medicine to treat insomnia.
With rising awareness of sleep disorders, more people are undergoing tests to understand the basics of their sleep disorder condition. Hospitals are opening new sleep centers and upgrading old ones. Patients are looking at innovative aspects in sleep centers which make them feel more homely.
Pharma companies are coming up with new sleeping disorder drugs. Gamma Aminobutyric Acid (GABA) agents dominate the insomnia market. More than a dozen insomnia drugs are in phase II and phase III clinical trials. Major products are Ambien, Ambien CR, Lunesta, Temazepam, and Zolpidem. Respironics and ResMed are the leading competitors in the continuous positive airway pressure (CPAP) market.
The report analyzes the sleep disorder treatment market. The focus is on OSA and insomnia treatment products. The report also profiles the major companies, with a discussion of their key business strategies. It also analyzes the major market and demographic trends prevalent in the sleep disorder treatment market.
Content
- 1. Sleep Disorders: An Introduction
- Sleep Cycle
- Amount of Sleep Required
- Sleep Disorders
- Insomnia
- Sleep Apnea
- Narcolepsy
- Restless Legs Syndrome
- Treatment & Diagnosis
- 2. Market Overview
- Worldwide Market
- US Market
- 2.1 OSA Market
- Sleep Disordered Breathing Market Breakup
- US Market for OSA Treatment
- 2.2 Insomnia Market
- 3. Market Trends
- 3.1 Use of Actigraphy for Sleep Disorder Evaluation
- 3.2 Alternative Medicines for Insomnia
- 3.3 Opportunities for HME Providers
- 3.4 Increasing Sleep Centers
- 4. Demographic Trends
- 4.1 Sleep Disorders in Older People
- 4.2 Sleep Disorders in Women
- 4.3 Sleep Disorders in Children
- 4.4 Sleep Concerns of Employees
- 5. Competitive Landscape
- 5.1 Insomnia Market
- Drugs in Pipeline for Insomnia
- Insomnia Market Activity
- Marketers of Insomnia Drugs
- Insomnia Market Share
- Characteristics of Drugs
- 5.2 OSA Market
- OSA Sales & Market Share
- Worldwide Market
- US Market
- 5.1 Insomnia Market
- 6. Company Profiles
- 6.1 Respironics
- Overview
- Business Strategies
- Product Innovation
- Strong Distribution Network
- International Growth
- 6.2 ResMed
- Overview
- Business Strategies
- Continued Product Development and Innovation
- Increase Public and Clinical Awareness
- Expansion into New Clinical Applications
- 6.3 Neurocrine
- Overview
- Business Strategies
- Building Product Portfolio
- Identifying Novel Drug Targets
- 6.4 Neurogen
- Overview
- Business Strategies
- Pursue a Risk-balanced Drug Portfolio
- Partnering at Optimal Stages
- Focus on Specialist Care Indications
- Total Sleep/Day by Age Group
- Classification of Sleep Disorders
- Worldwide Market for Sleep Disorder Treatment (2004-10E)
- US Sleep Diagnostic/Treatment Device Market (2005-07E)
- US Market for OSA Treatment (2003-07E)
- Sleep Disordered Breathing Market Breakup
- Insomnia Market Share - Drug Classes (2006)
- Non-Benzo/Non-Barbituate Market Share (2007)
- Sleep Disorder Facilities in the US (1996-2007)
- Employees Survey - Causes of Sleep Disturbance
- Drugs in Pipeline for Insomnia
- Insomnia Market Activity (2007)
- Current/Potential Marketers of Insomnia Drugs
- Characteristics of Drugs Marketed For Insomnia
- OSA Market Leaders - Market Share (2005-09E)
- OSA Market Leaders -US & International Sales (2005-09E)
- ResMed - CPAP Products
- Neurocrine - Product Pipeline
- Neurogen - Clinical Development Programs
- 6.1 Respironics
About this Product
Delivery Details
PDF:Delivered by email within 24 to 48 hours of placing the order (Mon-Fri)
Related Products
Recently Viewed Products
- FDA Investigates Possible Association Between anti-TNF Therapies and Cancer. >>
- Will Technological Improvements Eliminate Reliance on Heart Transplantation? >>
- Gene Therapy Drug Advexin to Face Regulatory Hurdles and Increasing Scepticism >>
- Pharma Companies Face Growing Competition Due to Ageing Population >>
Pharma & Healthcare
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Chemicals
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us
Resources
Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Meet Us
Jobs
Contact Us
Categories and Subcategories
















